Deniz Sahin - F Hoffmann La Roche Ltd

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 32 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Subgroup Analysis of Older Patients ≥60 Years with Diffuse Large B-cell Lymphoma in the Phase 3 POLARIX Study

Bei Hu,Patrick M Reagan,Laurie H Sehn,Jeff P Sharman,Mark Hertzberg,Huilai Zhang,Austin Kim,Charles Herbaux,Lysiane Molina,Dai Maruyama,Frank Stenner, Saibah Chohan, Rucha Kothari,Connie Lee Batlevi,Jamie Hirata,Deniz Sahin,Calvin Lee, Matthew Sugidono,Hervé Tilly

Blood advancesno. 10 (2025): 2489-2499

Cited0Views0WOSBibtex

Pola-R-CHP or R-CHOEP for First-Line Therapy of Younger Patients with High-Risk Diffuse Large B-cell Lymphoma: a Retrospective Comparison of Two Randomized Phase 3 Trials

Georg Lenz,Hervé Tilly,Marita Ziepert,Bettina Altmann,Charles Herbaux,Fabian Frontzek,Maike Nickelsen,Calvin Lee,Jamie Hirata,Deniz Sahin,Saibah Chohan,Connie Lee Batlevi,Mark Yan,Franck Morschhauser,Norbert Schmitz

Leukemiano. 12 (2024): 2709-2711

Cited0Views0WOSNATUREBibtex

A Comparison of the Prognostic Performance of the Lugano 2014 and RECIL 2017 Response Criteria in Patients with NHL from the Phase III GOYA and GALLIUM Trials

Lale Kostakoglu,Maurizio Martelli,Laurie H. Sehn,Andrew Davies,Marek Trneny,Michael Herold,Umberto Vitolo,Wolfgang Hiddemann,Judith Trotman,Andrea Knapp,Federico Mattiello,Tina G. Nielsen,Deniz Sahin,Gila Sellam,Carol Ward,Anas Younes

eJHaemno. 4 (2023): 1042-1051

Cited0Views0WOSBibtex

Table S1 from Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy

Laura M. Rogers,Sarah L. Mott,Brian J. Smith,Brian K. Link,Deniz Sahin,George J. Weiner

openalex（2023）

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn